Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Laser zaps annoying eye floaters in new study

NCT ID NCT06915922

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

This study tests a laser treatment for people with bothersome eye floaters that make vision blurry or distracting. Researchers will measure how vision, eye structure, and quality of life change after the procedure. The study involves 50 adults with floaters caused by certain eye conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

52 people

The number who actually took part.

Started

Oct 2023

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Only one eye per patient will be included in this study * Able and willing to give informed consent * Age ≥18 years * Suffering from symptomatic vitreous floaters * Floaters arising from either/both: * myopic vitreopathy * posterior vitreous detachment * Floaters meeting the following characteristics: * Present for ≥3 months * One single or more dense and well-defined vitreous opacities, * A Weiss Ring or opacities which are within the safety area, at least 3mm away from the retina and 6mm away from the lens * Visible on contact lens biomicroscopy Exclusion Criteria: * Patient presenting with vitreous opacities outside of the described safety area (within 3mm of the retina or 6mm from the lens) * Have clinically significant cataract (lens opacification) in one or both eyes which are in the opinion of the examining doctor more significant in impacting vision as compared to that caused by vitreous opacities; or cataract expected to need cataract surgery during the duration of the study * Present with untreated retinal tears or retinal holes requiring treatment at the discretion of the study investigator * Have high risk of peripheral lesions requiring treatment at the discretion of the study investigator * Have synchysis scintillans (unusual vitreous opacities from old blood) * Have asteroid hyalosis (unusual vitreous opacities from cholesterol) * Have vitreous hemorrhage (fresh blood in the center of the eye) * Have active photopsia (flashing lights) * History of previous YAG laser vitreolysis treatments, or vitrectomy for any condition (retinal detachment, proliferative diabetic retinopathy, etc.) * Have Posterior Vitreous Detachment (separation of vitreous away from the retina lining the inside of the back of the eye) within the past 3 months * Are unable to attend study appointments * Have any other significant ocular or non-ocular condition that, at the discretion of the study investigator, puts the subject at risk or influences the results of the study * History of intraocular surgery within 6 months from study entry * History of retinal laser within 2 months from study entry

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myopic vitreopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • VMR Institute for Vitreous Macula Retina

    Huntington Beach, California, 92647, United States